15P Intracranial (IC) efficacy of ivonescimab (ivo) plus chemotherapy (chemo) in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant, EGFR-mutated non-small cell lung cancer (NSCLC) in the HARMONi study

ESMO Open 2026 Open access

Read full text
Authors: X. Le, A. Passaro, J. Laskin, D. Rodriguez-Abreu, A. Calles Blanco, L. Bazhenova, G. Lo Russo, N. Leighl, F. Cappuzzo, N. Girard, S. Popat, W. Fang
+8 more Y. Luo, R. Yang, W. Li, HL West, Lori Styles, Junmin Li, J.W. Goldman, L. Zhang
DOI: 10.1016/j.esmoop.2026.106322
Cited by: 2

Abstract

HARMONi is a global randomized, double-blinded, phase III study evaluating the efficacy and safety of ivo + chemo vs placebo + chemo for patients (pts) with EGFR-mutated NSCLC whose disease has progressed on a 3rd-generation EGFR TKI. In the primary analysis, results showed longer progression-free survival (PFS) with ivo + chemo (hazard ratio [HR], 0.52 [95% confidence interval (CI), 0.41-0.66], P

Fields of Study & Subjects

Lung Cancer Treatments and Mutations Lung Cancer Research Studies Brain Metastases and Treatment

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
106322–106322
Publication date
17 March 2026
Language
EN